Background: Alzheimer's disease is characterized by two notorious protein aggregates in the brain: extracellular senile plaques mainly consisting of amyloid-β peptides and tau-protein-derived intracellular paired helical filaments. The diagnosis of Alzheimer's disease is impaired by insufficient sensitivity and specificity of diagnostic methods to visualize these pathological hallmarks over all disease stages. Objective: The established fluorescence marker methoxy-X04 stains plaques, tau tangles and amyloid-derived angiopathies with good specificity, yet it is limited by slow elimination in vivo. Since the need for new markers is high, we prepared methoxy-X04 derivatives and evaluated their potential as imaging agents in Alzheimer's disease pathology. Methods and Results: In this study, we describe an improved synthesis for methoxy-X04 and its derivatives and their affinity determination for the respective protein targets by immunohistology and a displacement assay. Conclusion: This resulted in the identification of new derivatives of methoxy-X04 with improved binding affinity.

Keywords:
Alzheimer’s disease, Fluorescence imaging, Tau, Amyloid-β, Histology
1.
Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63-67.
2.
Jakob-Roetne R, Jacobsen H: Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl 2009;48:3030-3059.
3.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
4.
Gravitz L: Drugs: a tangled web of targets. Nature 2011;475:S9-S11.
5.
Garber K: First FDA-approved beta-amyloid diagnostic hits the market. Nat Biotech 2012;30:575.
6.
Medeiros R, Baglietto-Vargas D, LaFerla FM: The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther 2011;17:514-524.
7.
Herholz K, Ebmeier K: Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011;10:667-670.
8.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang G-F, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
9.
Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT: Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002;61:797-805.
10.
Burgold S, Bittner T, Dorostkar Mario M, Kieser D, Fuhrmann M, Mitteregger G, Kretzschmar H, Schmidt B, Herms J: In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol 2011;121:327-335.
11.
Schafer Kelsey N, Kim S, Matzavinos A, Kuret J: Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study. Neuroimage 2012;60:1724-1733.
12.
Schmidt B, Kieser D, Bolaender A, Herms J, Heyny-von Haussen RH: Fluorescent ligands for protein aggregates and their use in the diagnosis of neurodegenerative diseases at the retina; Klinikum Darmstadt GmbH, Germany; Ludwig-Maximilians-Universität München; Technische Universität Darmstadt 2012, p 118.
13.
Bolaender A, Kieser D, Voss C, Bauer S, Schoen C, Burgold S, Bittner T, Hoelzer J, Heyny-von Haussen R, Mall G, Goetschy V, Czech C, Knust H, Berger R, Herms J, Hilger I, Schmidt B: Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease models. J Med Chem 2012;55:9170-9180.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.